These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10999764)

  • 1. Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo.
    Sirotnak FM; Wendel HG; Bornmann WG; Tong WP; Miller VA; Scher HI; Kris MG
    Clin Cancer Res; 2000 Sep; 6(9):3705-12. PubMed ID: 10999764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums.
    Khokhar NZ; She Y; Rusch VW; Sirotnak FM
    Clin Cancer Res; 2001 Oct; 7(10):3199-205. PubMed ID: 11595715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice.
    Sirotnak FM; DeGraw JI; Colwell WT; Piper JR
    Cancer Chemother Pharmacol; 1998; 42(4):313-8. PubMed ID: 9744777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
    Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-edged sword of chemosensitizer: increase of multidrug resistance protein (MRP) in leukemic cells by an MRP inhibitor probenecid.
    Kim HS; Min YD; Choi CH
    Biochem Biophys Res Commun; 2001 Apr; 283(1):64-71. PubMed ID: 11322768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of MRP and cMOAT in childhood neuroblastomas and malignant liver tumors and its relevance to clinical behavior.
    Matsunaga T; Shirasawa H; Hishiki T; Enomoto H; Kouchi K; Ohtsuka Y; Iwai J; Yoshida H; Tanabe M; Kobayashi S; Asano T; Etoh T; Nishi Y; Ohnuma N
    Jpn J Cancer Res; 1998 Dec; 89(12):1276-83. PubMed ID: 10081488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
    Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
    Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.
    Wang ES; O'Connor O; She Y; Zelenetz AD; Sirotnak FM; Moore MA
    Leuk Lymphoma; 2003 Jun; 44(6):1027-35. PubMed ID: 12854905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate and aminopterin lack in vivo antimalarial activity against murine malaria species.
    Irungu B; Kiboi D; Langat B; Rukunga G; Wittlin S; Nzila A
    Exp Parasitol; 2009 Oct; 123(2):118-21. PubMed ID: 19527714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 10-Ethyl-10-deaza-aminopterin: structural design and biochemical, pharmacologic, and antitumor properties.
    Sirotnak FM; Schmid FA; Samuels LL; DeGraw JI
    NCI Monogr; 1987; (5):127-31. PubMed ID: 2448650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins.
    Belinsky MG; Bain LJ; Balsara BB; Testa JR; Kruh GD
    J Natl Cancer Inst; 1998 Nov; 90(22):1735-41. PubMed ID: 9827529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter.
    Lee K; Belinsky MG; Bell DW; Testa JR; Kruh GD
    Cancer Res; 1998 Jul; 58(13):2741-7. PubMed ID: 9661885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice.
    Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
    Cancer Treat Rep; 1985 May; 69(5):551-3. PubMed ID: 4005878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP).
    Versantvoort CH; Bagrij T; Wright KA; Twentyman PR
    Int J Cancer; 1995 Dec; 63(6):855-62. PubMed ID: 8847145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors.
    Fury MG; Krug LM; Azzoli CG; Sharma S; Kemeny N; Wu N; Kris MG; Rizvi NA
    Cancer Chemother Pharmacol; 2006 May; 57(5):671-7. PubMed ID: 16136310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MOAT-E (ARA) is a full-length MRP/cMOAT subfamily transporter expressed in kidney and liver.
    Belinsky MG; Kruh GD
    Br J Cancer; 1999 Jul; 80(9):1342-9. PubMed ID: 10424734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.
    Krug LM; Azzoli CG; Kris MG; Miller VA; Khokhar NZ; Tong W; Ginsberg MS; Venkatraman E; Tyson L; Pizzo B; Baez V; Ng KK; Sirotnak FM
    Clin Cancer Res; 2003 Jun; 9(6):2072-8. PubMed ID: 12796370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis study.
    Sani SN; Henry K; Böhlke M; Kim J; Stricker-Krongrad A; Maher TJ
    Cancer Chemother Pharmacol; 2010 May; 66(1):159-69. PubMed ID: 19816684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts.
    Tedeschi PM; Kathari YK; Farooqi IN; Bertino JR
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1029-32. PubMed ID: 25205429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.